表紙
市場調査レポート

EpiCast Report:髄膜炎菌性疾患の疫学的予測

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025

発行 GlobalData 商品コード 270722
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
EpiCast Report:髄膜炎菌性疾患の疫学的予測 EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025
出版日: 2016年06月01日 ページ情報: 英文 82 Pages
概要

当レポートでは、世界の主要国における髄膜炎菌性疾患 (髄膜炎菌性髄膜炎など) の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の罹患・普及状況、今後10年間の発症件数の予測値などを調査・推計しております。

第1章 目次

第2章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界各国の動向
    • 米国
    • EU主要5ヶ国
    • 日本・ブラジル
  • 予測手法
    • 利用した情報源
    • 予測の仮定・手法
    • 利用しなかった情報源
  • 侵襲性髄膜炎菌性疾患 (IMD) の疫学的予測:今後11年間分
    • IMDの発症者数総数
    • 発症率 (セログループBの場合)
    • 発症率 (セログループCの場合)
    • 発症率 (セログループYの場合)
    • 発症率 (その他のセログループの場合)
    • セログループに関する議論
    • 米国の大学1年生の場合
  • 議論
    • 疫学的傾向に関する結論
    • 分析の限界
    • 分析の強み

第3章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER118-16

Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.

In the 8MM, GlobalData epidemiologists forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. GlobalData epidemiologists estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.

Scope

  • The Meningococcal disease (IMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1-4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation.
  • The IMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The IMD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IMD market.
  • Quantify patient populations in the global IMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IMD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Disease Background
  • 2.2. Risk Factors and morbidities
  • 2.3. Global Trends
    • 2.3.1. US
    • 2.3.2. 5EU
    • 2.3.3. Japan and Brazil
  • 2.4. Forecast Methodology
    • 2.4.1. Sources Used Tables
    • 2.4.2. Forecast Assumptions and Methods
    • 2.4.3. Sources Not Used
  • 2.5. Epidemiological Forecast for IMD (2015-2025)
    • 2.5.1. All IMD Combined
    • 2.5.2. Laboratory-Confirmed Incident Cases of Serogroup B IMD
    • 2.5.3. Laboratory-Confirmed Incident Cases of Serogroup C IMD
    • 2.5.4. Laboratory-Confirmed Incident Cases of Serogroup Y IMD
    • 2.5.5. Laboratory-Confirmed Incident Cases of Other Serogroup IMD
    • 2.5.6. Distribution of Serogroups
    • 2.5.7. US College Freshmen
  • 2.6. Discussion
    • 2.6.1. Epidemiological Forecast Insight
    • 2.6.2. Limitations of the Analysis
    • 2.6.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologists
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for IMD
  • Table 2: 8MM, Sources of Laboratory-Confirmed IMD Incidence
  • Table 3: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence
  • Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence
  • Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence
  • Table 6: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W-135, X, and All Others)
  • Table 7: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W-135 IMD Incidence
  • Table 8: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence
  • Table 9: College Freshmen Residing in Campus Accommodation
  • Table 10: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 11: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 12: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 13: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015
  • Table 14: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 17: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 18: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025

List of Figures

  • Figure 1: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014
  • Figure 2: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 3: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015
  • Figure 4: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015
  • Figure 5: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015
  • Figure 6: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 7: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 10: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015
  • Figure 11: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025
  • Figure 12: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
Back to Top